Takeda Finishes Construction of Manufacturing Facility in Germany
Takeda inaugurated expanded capacity of solid-dosage drugs at its site in Oranienburg, Germany.
Takeda Pharmaceutical Company has completed the construction of new manufacturing facilities at its site in Oranienburg, Germany, the company announced on June 16, 2017. The new, 21,400-m2 production facility was built at a total cost of around 100 million euros and is scheduled to begin operating at the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.
In a press release issued November 27, 2014, Takeda announced that, as a part of its initiative toward optimization of its global network, the manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The completion of this new manufacturing facility in Germany is an integral part of this effort.
Specialized in producing solid forms (pills and capsules), the Oranienburg site, which has a 130-year history of pharmaceutical production in Germany, plays a key role in Takeda’s global manufacturing network. Many of Takeda’s drug products are manufactured and supplied to 100 countries worldwide from the Oranienburg site. The expanded production capacity of the Oranienburg site will make it possible to meet the increased demand for Takeda’s products in global markets, including rapidly growing emerging markets, and has already created about 180 new jobs.
Source: Takeda
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
